The computational pathology technology provider has added $25m to a round co-led by Johnson & Johnson Innovation – JJDC.

Novo will exit the musculoskeletal disease drug developer, should the latter complete an initial public offering on the Nasdaq Global Market.

SR One is line for an exit from the small-molecule therapy developer, which has raised $170m in venture funding in the past year.

The immuno-oncology company, based on University of Turin research, has completed a $21m series B round led by Claris Ventures.

Max Planck spinout Quench Bio will wind down after its target proved undruggable and will return capital to investors, which include AbbVie Ventures.

Astellas Venture Management is among the new investors in the cancer immunotherapy developer, which was spun off by PhoreMost four years ago.

Quench Bio will wind down after its protein target proved undruggable and will return capital to investors including AbbVie Ventures.

The Kaiser Permanente-backed healthcare engagement platform developer pushed its overall funding past $350m and its valuation to $3.2bn.

The pharmaceutical firm is joining forces with China International Capital Corporation, the investment bank with which it launched a $1bn fund in 2019.

Kakao Ventures and SK Holdings have returned to back the AI and data-infused drug discovery technology provider in a $44.5m round.